Samer Al Hadidi/UT Southwestern Simmons Cancer Center's LinkedIn
Mar 20, 2026, 16:22
Welcoming Samer Al Hadidi to the Blood Cancers Team – UT Southwestern Simmons Cancer Center
UT Southwestern Simmons Cancer Center shared a post on LinkedIn:
”Please join us in welcoming Samer Al Hadidi, M.D., to our blood cancers team.
He specializes in hematology and oncology, with an emphasis on plasma cell disorders, including multiple myeloma and light chain amyloidosis, and cellular therapies, including CAR T-cell therapy and hematopoietic stem cell transplantation.
Dr. Al Hadidi is the Clinical Director of the Amyloidosis Program at UT Southwestern.
He also serves as Leader of the Fellows’ Plasma Cell Disorders Clinic.
He is nationally recognized as an expert in treating multiple myeloma and utilizing cellular therapies for plasma cell disorders.
Learn more about Dr. Al Hadidi.”
Stay updated with Hemostasis Today.
-
Mar 20, 2026, 16:31Jerome Winegarden: ASH Continues to Show Exceptional Leadership by Advocating for Patients With Blood Diseases
-
Mar 20, 2026, 16:28Breanna Beers: A Remarkable Case of ‘Generation Skipping’ Marfan Syndrome
-
Mar 20, 2026, 16:26Results from The HUNT Study on The Role of Plasma miR-145-5p Levels in Cancer-Associated VTE – JTH
-
Mar 20, 2026, 16:23Eva Soler Espejo։ Atherogenic Index of Plasma and Residual Risk in Atrial Fibrillation
-
Mar 20, 2026, 16:21Maxime Dely: The Lifesaving Power of Plasma Donations
-
Mar 20, 2026, 16:20Yves Bikorimana: Hemolysis – Why It Ruins Laboratory Results
-
Mar 20, 2026, 16:19Simon Senanu: G6PD Deficiency Testing – What the Lab Must Get Right
-
Mar 20, 2026, 16:18Khaled Elshazly: Can We Stop Chemotherapy-Induced Thrombocytopenia from Delaying Treatment?
-
Mar 20, 2026, 15:50Rithwic Mani: Platelet-to-Lymphocyte Ratio as A Simple and Cost-Effective Prognostic Biomarker in Stroke